CGTH-W-1

Cat.No.: CSC-C0412

Species: Homo sapiens (Human)

Source: Thyroid Gland

Morphology: adherent large epitheloid cells with long processes growing in monolayers with multilayer foci

Culture Properties: monolayer

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C0412
Description
Established from the sternal metastasis of follicular thyroid carcinoma removed from a 70-year-old Chinese woman in 1993; described to carry IGF-1 receptors
Species
Homo sapiens (Human)
Source
Thyroid Gland
Recommended Medium
Culture Properties
monolayer
Morphology
adherent large epitheloid cells with long processes growing in monolayers with multilayer foci
Karyotype
Human hypertriploid karyotype with 10% polyploidy - 77(72-78)<3n>XX, -X, +1, +3, +3, +6, +8, +16, -17, -21, +5mar, del(X)(q25)x2, del(1)(q22), t(3;10)(p11;q11), ?del(4) (q21), del(6)(p11p21), del(7)(p14), i(9q), ?del(10)(q21/24), der(11)t(11;14)(q24;q12),
Disease
Thyroid Gland Squamous Cell Carcinoma
Quality Control
Mycoplasma: contamination was eliminated with BM-Cyclin (tiamulin & minocycline), then negative in DAPI, microbiological culture, RNA hybridization assays
Immunology: cytokeratin -, cytokeratin-7 -, cytokeratin-8 -, cytokeratin-17 -, cytokeratin-18 -, des
Storage and Shipping
Frozen with 70% medium, 20% FBS, 10% DMSO at about 2 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen
Synonyms
CGTH-W1; CGTH W-1; CGTHW1
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

CGTH-W-1 (formerly known as W-1) is a human thyroid carcinoma cell line first described as being established from the sternal metastasis of follicular thyroid carcinoma from an elderly woman. It is commonly used as an in vitro model of thyroid cancer, specifically follicular thyroid carcinoma and poorly differentiated thyroid carcinoma. Cells maintain adherent epithelial morphology and grow as monolayers. Cells have relatively fast doubling times of ~18-25 hours. Molecular analyses have identified driver mutations such as TP53 and TERT promoter mutations that are commonly seen in aggressive thyroid cancers. Initial characterization of the CGTH-W-1 cell line showed that they express insulin-like growth factor-1 receptors and utilize IGF-1 signaling pathways. This made CGTH-W-1 useful to study growth factor-mediated tumor progression in vitro.

CGTH-W-1 was recently used in studies along with FTC-133 and BcPAP thyroid cancer cell lines to study gene regulation and extracellular vesicle-mediated signaling as well as interactions with tumor microenvironments. They have also been used for proteomic analysis and functional analysis including spheroid formation and cytoskeletal dynamics under varying physical conditions. CGTH-W-1 has been reported to be misidentified or cross-contaminated cell line and is a derivative of SW579.

PROX1 Knock-Down CGTH-W-1 Cells and Its Effect on Cell Motility and Invasive Potential

Prospero homeobox 1 (PROX1), a master regulator of lymphangiogenesis, is an implicated carcinogenic transcription factor. Its role in tumorigenesis and metastasis, however, is not well understood. In this study, Rudzińska et al. analyzed the role of PROX1 in thyroid tumorigenesis utilizing PROX1-siRNA-transfected follicular-derived thyroid cancer cell line CGTH-W-1. Effects of PROX1 depletion were analyzed on proliferation, cell cycle, apoptosis, and cell motility.

siRNA knockdown of PROX1 was validated by RT-qPCR, western blot, and immunocytochemistry. PROX1 transcript and protein levels were reduced by greater than 90% relative to non-silencing control siRNA-treated cells (Figure 1). Silencing of PROX1 led to statistically significant decreases in migration and invasion (>2-fold reduction, p < 0.0001) in consistently replicated experiments (Figure 2a, b).

Actinomycin-D-treated wound healing assays revealed PROX1 silencing significantly inhibited migration of cells (p = 0.0001), resulting in a 6.6-fold decrease in migrating cells with or without inhibition of proliferation (Figure 2c). Loss of PROX1 resulted in dramatic cytoskeletal reorganization visualized by immunofluorescence including alteration of cellular morphology and decreases in stress fibers and cell protrusions.

The efficiency of PROX1 knockdown (48 h) with siRNA in CGTH-W-1 cells derived from follicular thyroid cancer (sternal metastasis).

Fig. 1. The efficiency of PROX1 knockdown (48 h) with siRNA in CGTH-W-1 cells derived from follicular thyroid cancer (sternal metastasis) (Rudzińska M, Grzanka M, et al., 2019).

The effect of PROX1 knock-down on the migration (a), invasion (b) and wound healing capacities (c) of CGTH-W-1 follicular thyroid cancer cells determined by Boyden chamber migration, Matrigel invasion and wound-healing assay, respectively.

Fig. 2. The effect of PROX1 knock-down on the migration (a), invasion (b) and wound healing capacities (c) of CGTH-W-1 follicular thyroid cancer cells determined by Boyden chamber migration, Matrigel invasion and wound-healing assay, respectively (Rudzińska M, Grzanka M, et al., 2019).

Ask a Question

Write your own review

  • You May Also Need

For research use only. Not for any other purpose.

Hot Products